Financial Results As of March 31, 2025, the company’s cash, cash equivalents, and marketable securities were $23.2 million. Total operating expenses for the quarter ended March 31, 2025 were $12.9 ...

Armando Castro, partner, emerging companies, venture capital, Lowenstein Sandler, explains how repurposing GLP-1s and ...

On May 7, 2025, Y-mAbs announced that naxitamab-gqgk (DANYELZA ®) has been recommended by the National Comprehensive Cancer Network ® ("NCCN”) Clinical Practice Guidelines in Oncology (NCCN Guidelines ...

California Told Companies to Label Toxic Chemicals. Instead They’re Quietly Dropping Them Businesses are making moves to ...

As part of its attempt to force food companies to voluntarily stop using artificial food dyes, the FDA has approved three dyes that it says come from ...

Q1 2025 Management View CEO Denny Lanfear stated the company has completed its biosimilar divestitures and is now “fully focused on innovative oncology,” positioning itself as a commercial-stage ...

FDA Commissioner Martin Makary sounded the alarm on tianeptine, also known as "gas station heroin," and its growing adverse ...

Arrowhead Pharmaceuticals prepares for the 2025 commercial launch of plozasiran, bolstered by a $1.375B Sarepta deal, advancing pipeline, and ...

The best metric is not weight, but a particularly toxic kind of fat.

There’s a “pretty good body of literature” suggesting that these three new color additives — called Galdieria extract blue, ...

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...